Donate to finance clinical trials that are too risky for venture capitalists
We are not a 501(c)(3) organization and your donations are not tax-deductible.
Alzheimer’s disease and dementia rob millions of people of their memories, independence, and identity, and yet the venture capital is often hesitant to finance the boldest ideas—the ones that might actually change the game—because they’re seen as “too risky”.
At Metallomix, we know that challenging the status quo does not come from playing it safe. Our founders invested millions in exactly that — a new therapeutic approach targeting one of the disease’s root causes, the brain’s intracellular zinc biology. Now, when our unorthodox scientific stance is supported by compelling third-party data, we are seeking like-minded investors and donors to help us advance this breakthrough through early-stage clinical research—where philanthropic support can make the greatest difference. Your contribution will help to accelerate the transition from preclinical to clinical science that could preserve memory, dignity, and life itself for millions of families around the world.
